ASCO in retrospect - Sharing Best Practice


ASCO 2023
ADC revolution: How can the new results be integrated…


ASCO 2023
CDK4/6i in EBC: Have abema and ribo arrived in the…


Sonia Trial
ACSO 2023
Sonia trial: How does the new data change clinical…


ASCO 2023
Discussions and controversies on social-media: what is…
Early breast Cancer - Discussions ENG


SOFT
ASCO 2023
PART2: Trying to understand optimal therapy for…


NATALEE, MonarchE, PENELOPE-B
ASCO 2023
CDK4/6 inhibitors in EBC: Amazing data, but longer…


NATALEE
ASCO 2023
Expanding CDK4/6i therapy in EBC: How to select…


PHERGain
ASCO 2023
PART1: How to de-escalate chemotherapy? What is the…
Perspectives of EBC treatment


Meta Analyses
ASCO 2023
Data from Meta-Analyses of almost 15k Patients: Who…


NATALEE
ASCO 2023
New data on Ribocilib in adjuvant setting EBC: What…


PHERGain
ASCO 2023
Chemotherapy de-escalation in HER2+ patients:…
Breast cancer early - 100 seconds ENG


TORCHLIGHT
ASCO 2023
Another proof of efficacy of immunotherapy in advanced…


PHERGain
ASCO 2023
De-escalation of CT for early BC


ShortHER
ASCO 2023
10 years update on ShortHER


PHERgain
ASCO 2023
Response adapted, chemotherapy-free option in HER2+ EBC


NATALEE
ASCO 2023
Practice changing or not quite yet?


PHERGain
ASCO 2023
PHERGain opens the possibility to avoid chemotherapy in…


PENELOPE-B
ASCO 2023
Tumor-informed ctDNA likely prognostic for relapse in…


NeoPACT
ASCO 2023
Chemo-immunotherapeutic signals especially in HER2low…


NATALEE, MonarchE, PENELOPE-B
ASCO 2023
My EBC highlights from ASCO23


ASCO 2023
TILs are prognostic but not predictive in HER2+ EBC


NATALEE
ASCO 2023
First data with adjuvant ribociclib


NATALEE
ASCO 2023
Ribociclib improves iDFS


ASCO 2023
TILs in HER2+ disease - prognostic, but not enough to…


RUBY
ASCO 2023
Checkpoint inhibition in endometrial cancer: new…


PENELOPE-B
ASCO 2023
Analyses of ctDNA in PENELOPE-B: Test methods are…


NATALEE, MonarchE
ASCO 2023
Early follow-up shows clear benefit


PHERGain
ASCO 2023
Can we preserve our patients form chemotherapy?


PALMIRA
ASCO 2023
Palbociclib after Palbociclib might not be the best…


ASCO 2023
Ovarian function - Ovarian suppression not necessary in…


NATALEE, MonarchE, PENELOPE-B
ASCO 2023
Discussions on CDK4/6 inhibitors in EBC


PENELOPE-B
ASCO 2023
From PENELOPE-B to SURVIVE


PHERGain
ASCO 2023
1/3 of patients with HER2+ in future without…


Meta-Analyses, SOFT
ASCO 2023
Young patients benefit from ovarian suppression


NATALEE
ASCO 2023
Ribociclib has arrived in the adjuvant setting


ASCO 2023
TILs subtypes are associated with clinical features and…


GeparNuevo
ASCO 2023
White blood cells with increasing prognostic relevance?…


PHERGain
ASCO 2023
A challenge for clinical management


ASCO 2023
SOC of ovarian ablation confirmed in meta-analysis.


NATALEE
ASCO 2023
More CDK4/6 options for EBC patients
Breast Cancer early 100 seconds - multi language


ASCO 2023
TILs w rakach HER2+ - znaczenie rokownicze, ale nie…


PENELOPE-B
ASCO 2023
Von PENELOPE-B zur SURVIVE


NATALEE
ASCO 2023
Eine Herausforderung für viele Patienten, wenig…


ASCO 2023
SOC der ovarialen Ablation in der Metaanalyse bestätigt


NATALEE
ASCO 2023
Primele date cu ribociclib adjuvant


NATALEE
ASCO 2023
NATALEE nicht überraschend aber überzeugend positiv


PHERgain
ASCO 2023
1/3 der Patientinnen mit HER2+ zukünftig ohne…


PHERGAIN
ASCO 2023
Response adaptierte, Chemotherapie-freie Option beim…


PHERGain
ASCO 2023
Eine Herausforderung für das klinische Management


ASCO 2023
TILs Subtypen sind assoziiert mit klinischen Merkmalen…


NeoPACT
ASCO 2023
Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…


TORCHLIGHT
ASCO 2023
Kolejny dowód na skuteczność immunoterapii w…


PENELOPE-B
ASCO 2023
Tumor-informed ctDNA wahrscheinlich prognostisch für…


ASCO 2023
Ovar Funktion - Ovarielle Supression verzichtbar bei…


NATALEE
ASCO 2023
Czy wystarczy, aby zmienić standardy?


PHERGain
ASCO 2023
PHERGain abre la posibilidad de evitar la quimioterapia…


ASCO 2023
TILs sind prognostisch aber nicht prädiktiv beim HER2+…


NATALEE, MonarchE, PENELOPE-B
ASCO 2023
I miei punti salienti di ASCO23


PALMIRA
ASCO 2023
Palbociclib después de Palbociclib podría no ser la…
Breast cancer metastatic - 100 seconds ENG


TROPiCS-02
ASCO 2023
Continued OS benefit for Sacituzumab Govitecan


PreCycle
ASCO 2023
E-Health Applications in Oral Cancer Therapy


18F-FES
ASCO 2023
Molecular imaging for endocrine responsivness


TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04
ASCO 2023
Updates on ADCs in metastatic breast cancer


PADA-1
ASCO 2023
The start of precision medicine in HR+ breast cancer


PALMIRA, MAINTAIN (ASCO22), PACE (SABCS22)
ASCO 2023
CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle


SONIA
ASCO 2023
What is the optimal therapie sequence for HR+ MBC…
Breast cancer metastatic 100 seconds - multi language


PALMIRA, MAINTAIN (ASCO22), PACE (SABCS22)
ASCO 2023
CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…


TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04
ASCO 2023
Mises à jour sur les ADC dans le cancer du sein…


TROPiCS-02; HER3-dXD; Destiny-Breast 02, 03, 04
ASCO 2023
Aggiornamenti sugli ADC nel carcinoma mammario…
MBC - Discussions


SONIA, PALMIRA, PADA-1
ASCO 2023
CDK4/6 Sequencing? ESR-1 not ready for prime time?…


CANKADO
ASCO 2023
The value of eHealth


SONIA, PALMIRA, PADA-1
ASCO 2023
CDK4/6i in first line and beyond & Biomarkers


TROPICS-02, HER3 DxD
ASCO 2023
Update ADC efficacy
Prostate cancer - 100 seconds eng


PEACE-1
ASCO 2023
PEACE 1 - results and controversies


ARASEC
ASCO 2023
ARASEC: ADT + Daralutamide for mHSPC


ASCO 2023
Over-staging of bone scan compared with PSMA PET/CT


ASCO 2023
Metastasis-directed for prostate cancer


TALAPRO-2
ASCO 2023
Confirming results for PARPi in mCRPC


DEAR
ASCO 2023
DEAR trial: real-world comparator analyses of ARIs


NRG/RTOG
ASCO 2023
AI for prediction in local prostate carcinoma


ICECAP
ASCO 2023
PSA nadir 6 month after Radiotherapy is strong…


Educational Session PCA
ASCO 2023
Intensified or de-intensified therapy in mHSPC


PRL02
ASCO 2023
PRL-02: Intramuscular arbiraterone


TALAPRO-2
ASCO 2023
TALAPRO-2: Results and controversies


TRANSPORT
ASCO 2023
Part2: Important update on testosterone-recovery


REASSURE
ASCO 2023
Reassuring real-world data!


TALAPRO-2
ASCO 2023
PAPR-inhibitors: Patient-selection matters!


LuPARP
ASCO 2023
LuPARP combination study: LuPSMA and Olaparib in mCRPC


TRANSPORT
ASCO 2023
Part 1: Important update on testosterone-recovery
Prostate Cancer 100 seconds - multi language


Educational Session PCa
ASCO 2023
Intensifierad eller de-intensifierad behandling vid…


TALAPRO-2
ASCO 2023
Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC


ASCO 2023
Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT


ICECAP
ASCO 2023
PSA nadir 6 månader efter radioterapi är en prognostisk…


TALAPRO-2
ASCO 2023
PARP-inhibitors: La selección de pacientes es…


LuPARP
ASCO 2023
LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC
Prostate cancer - Discussions ENG


PEACE-1
ASCO 2023
Triple therapy in mCSPC - which is the ideal partner…


TALAPRO-2
ASCO 2023
PARPi in PCa: more genetic testing is required as PRO…


ASCO 2023
What is your preferred sequence in 1st line treatment…
Bladder cancer - 100 seconds ENG


THOR
ASCO 2023
The beginning of a new era in urothelial cancer?!


JAVELIN BLADDER 100
ASCO 2023
Q-TWiST in the therapy of aUC


VESPER, THOR, SWOG S1011, NORSE
ASCO 2023
Best of Bladder: ddMVC increases DFS! Standard…


EV-103
ASCO 2023
Enfortumab vedotin + pembrolizumab 1stL in…


SWOG S1011
ASCO 2023
Extent of lymphadenectomy in cystectomy


VESPER
ASCO 2023
New standard for MIBC


THOR
ASCO 2023
FGFR inhibition


EV-103
ASCO 2023
First line in cisplatin-ineligible advance urothelial…


THOR
ASCO 2023
Targeted therapies in advanced urothelial cancer: The…


THOR
ASCO 2023
New SoC option for metastatic bladder cancer
Bladder cancer 100 second - multi language


EV-103
ASCO 2023
Primera línea en cáncer urotelial avanzado no elegible…


VESPER, THOR, SWOG S1011, NORSE
ASCO 2023
Best of Bladder: ddMVC increases DFS! Standard…


THOR
ASCO 2023
Nouvelles options de soins standard pour le cancer de…


THOR
ASCO 2023
Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…
Bladder cancer - Discussions


VESPER
ASCO 2023
The efficacy of neo-adjuvant therapy (ddMVAC,…


Study EV-103, JAVELIN Bladder 100
ASCO 2023
Update EV/Pembro, Avelumab Maintenance


THOR, NORSE, PROOF 302
ASCO 2023
The efficacy of FGFR targeting
Kidney cancer - Discussions


CONTACT-03
ASCO 2023
Primary endpoint not reached: what do we learn from…


CBM588
ASCO 2023
The impact of microbiome and supplements on therapy…


Keynote-426 CLEAR
ASCO 2023
Long term follow up in advanced renal cell cancer: Is…


KEYNOTE-B61
ASCO 2023
Non ccRCC: how should we treat patients today?
Kidney cancer - 100 seconds eng


Keynote-426, CLEAR
ASCO 2023
Long-term follow-up for IO/TKI in mRCC


Keynote-426, CLEAR
ASCO 2023
1st Line therapy RCC: which combination to choose?


CONTACT-03
ASCO 2023
New standard for 2nd line RCC?


CheckMate 314
ASCO 2023
News from the adjuvant


KEYNOTE-426, CLEAR
ASCO 2023
Update and take home message of 1st Line mRCC


KEYNOTE-B61
ASCO 2023
Lenvatinib + pembrolizumab in non-clear cell renal cell…


KEYNOTE-B61
ASCO 2023
New data non ccRCC


CONTACT-03
ASCO 2023
IO rechallenge in mRCC
NSCLC early stages - Discussion


ADAURA
ASCO 2023
ADAURA: Osimertinib improves survival in the treatment…


CheckMate 816, IMpower010, KEYNOTE-671, NEOTORCH
ASCO 2023
The value of perioperative chemo-IO in rNSCLC and the…
NSCLC early stages - 100 seconds ENG


ADAURA, KEYNOTE-671
ASCO 2023
More options in the perioperative setting


ADAURA
ASCO 2023
EGFR testing necessary in the adjuvant setting


KEYNOTE-671
ASCO 2023
Added benefit of perioperative chemo/IO in stage 2-3b…


ADAURA
ASCO 2023
A new standard of care


KEYNOTE-671
ASCO 2023
Which should we prefer: neoadjuvant, adjuvant or…


ADAURA
ASCO 2023
ADAURA - results and controversies


ADAURA
ASCO 2023
A new standard of care for operated patients with…


ADAURA
ASCO 2023
An imperfect analysis, but perfect results


CheckMate 9LA
ASCO 2023
CheckMate 9LA: 4‑year clinical update


IMpower010
ASCO 2023
Adjuvant IO in KRASm patients


ADAURA
ASCO 2023
ADAURA - Discussion closed?


EAST ENERGY
ASCO 2023
A chemo-free preop. IO strategy?


CheckMate 816, ADAURA
ASCO 2023
Adjuvant and neoadjuvant strategies in resectable NSCLC


KEYNOTE-671, NEOTORCH
ASCO 2023
Induction options in the perioperative setting


KEYNOTE-671
ASCO 2023
Perioperative treatment


KEYNOTE-671
ASCO 2023
Role of periopertative IO confirmed


KEYNOTE-671, CheckMate-816
ASCO 2023
Confirmation of neoadjuvant immunotherapy


ADAURA
ASCO 2023
OS benefit from EGFR receptor TKI


KEYNOTE-671
ASCO 2023
Another neoadjuvant chemo/IO option
NSCLC early stages 100 seconds - multi language


KEYNOTE-671
ASCO 2023
Toegevoegde waarde van periperatief chemo-immuno bij…


ADAURA
ASCO 2023
Un nouveau standard therapeutique pour les patients…


ADAURA, KEYNOTE-671
ASCO 2023
Más opciones en el entorno perioperatorio


KEYNOTE-671
ASCO 2023
Que devrions-nous préférer: traitement néoadjuvant,…


ADAURA
ASCO 2023
ADAURA- discussie gesloten?


CheckMate 816, ADAURA
ASCO 2023
Stratégies adjuvantes et néoadjuvantes dans le CBNPC…


KEYNOTE-671
ASCO 2023
Rolle der periopertativen IO bestätigt
NSCLC metastatic - Discussions


CodeBreaK 200
ASCO 2023
Sotorasib: clear clinical benefit, but short follow-up…


ASCO 2023
Zorifertinib: an option when osimertinib is not…


SCARLET, KontRASt-01
ASCO 2023
Update on KRASG12Cm treatment options - how to proceed?


LUNAR
ASCO 2023
TTF-treatment requires further studies


KEYNOTE-789
ASCO 2023
Pembro + chemo in pts with TKI-resistant EGFRm /…


TROPION-Lung02
ASCO 2023
Does ADC + chemo + IO replace the existing concepts?
NSCLC metastatic - 100 seconds eng


LUNAR
ASCO 2023
LUNAR: TTF medical device shows OS-benefit, but more…


TROPION-Lung02
ASCO 2023
ADC + ICI ± Pt-CT in patients with aNSCLC


TROPION-Lung02
ASCO 2023
TROP2-ADC shows high response rates in 1L-combination…


CORRELATE
ASCO 2023
CORRELATE - a real world analysis


KEYNOTE-789
ASCO 2023
IO in EGRF positive patients post TKI


ASCO 2023
Stopping treatment is ok
SCLC - Discussions


ASCO 2023
Hyperfractionation - an interestingh concept, but not…


ASCO 2023
New data from another BiTE
SCLC - 100 seconds ENG


SWOG 1929
ASCO 2023
Treatment strategies in SCLC


ASCO 2023
More BiTEs, more possibilities


ASCO 2023
Hyperfractionated radiotherapy for SCLC


SWOG 1929
ASCO 2023
Can we incoporate biomarkers in SCLC treatment?


SWOG 1929
ASCO 2023
A positive trial with no impact
SCLC 100 seconds - multi language


SWOG 1929
ASCO 2023
Kunnen we biomarkers gebruiken om behandeling te…


ASCO 2023
Más BiTEs, más posibilidades


SWOG 1929
ASCO 2023
Stratégies de traitement dans le SCLC
Varia 100 seconds - ENG


PROspect
ASCO 2023
ONCOalert (inclusive patient advocates) consensus on…


IND277
ASCO 2023
No practice-changing data in mesothelioma, other…


IND227
ASCO 2023
Immune checkpoint inhibitors in malignant mesothelioma
Varia 100 seconds - Multi language


IND227
ASCO 2023
Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!